Benefits And Science

TUDCA reduced artery narrowing after injury, plaque and aneurysm size in rats, rabbits and mice. No human artery trial exists. What each study tested.

TUDCA reduced brain lesions and inflammation in rodent brain injury models, but one TBI study was retracted and no human trial exists.

TUDCA reduced lung fibrosis and allergic airway inflammation in mice, but no human lung trial exists. What each study tested and where it stops.

In PCOS mice, TUDCA reduced granulosa cell death, ovarian fibrosis and cycle disruption. No trial has tested it in women, and pregnancy safety is unknown.

TUDCA protected cartilage and spinal disc cells from ER stress in lab studies, but one study found no effect on cell death. No human joint trial exists.

TUDCA lowered blood pressure in several rat and mouse models of hypertension. No human trial has measured blood pressure, and two small vessel studies split.

TUDCA improved metabolism and cognition in aged mice at 300 mg/kg. Two key studies used intravenous or intracerebroventricular dosing, not capsules.

TUDCA reduced seizure severity in two rat models at 500 mg/kg injected. There are no human trials, and epilepsy drugs must not be self-adjusted.

A 150-patient randomised trial cut liver enzymes on TUDCA. A Cochrane review of 27 trials found no effect on the virus and worse histology scores.

TUDCA tightened the gut barrier in mice, pigs and cell lines through TGR5. Every study is an animal model, and leaky gut is not a diagnosis.

TUDCA preserved trabecular bone in ovariectomised mice, but the serum bone turnover markers missed significance and no human trial exists.

One of the few human trials of TUDCA itself tested it in infants on parenteral nutrition and found no effect. Why it failed is the useful part.